PT Kalbe Farma TbkFRA:LCLA +40.30%77 Days Payable is 39.00 as of Mar. 2026, which is 7% above its 10-year median of 36.45. GuruFocus rates FRA:LCLA with a GF Score™ of 77/100 and a GF Value™ of €0.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 920 Drug Manufacturers companies, PT Kalbe Farma Tbk ranks worse than 84.67% on this metric.
The historical rank and industry rank for PT Kalbe Farma Tbk's Days Payable or its related term are showing as below:
FRA:LCLA'
s Days Payable Range Over the Past 10 Years
Min: 32.91 Med: 36.45 Max: 40.54
Current: 38.13
During the past 13 years, PT Kalbe Farma Tbk's highest Days Payable was 40.54. The lowest was 32.91. And the median was 36.45.
FRA:LCLA's Days Payable is ranked worse than 84.67% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs FRA:LCLA: 38.13
PT Kalbe Farma Tbk's Days Payable
increased
from Mar. 2025 (36.52) to Mar. 2026 (39.00).
It may suggest that PT Kalbe Farma Tbkdelayed paying its suppliers.
PT Kalbe Farma Tbk Days Payable Related Terms
PT Kalbe Farma Tbk Days Payable Historical Data
* Premium members only.
The historical data trend for PT Kalbe Farma Tbk's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LCLA vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, PT Kalbe Farma Tbk's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kalbe Farma Tbk Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Kalbe Farma Tbk's Days Payable distribution charts can be found below:
* The bar in red indicates where PT Kalbe Farma Tbk's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
PT Kalbe Farma Tbk's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kalbe Farma Tbk (FRA:LCLA) has a Days Payable of 39.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PT Kalbe Farma Tbk and its competitors. This is near median its historical median of 36.45. Over the past decade, PT Kalbe Farma Tbk's Days Payable has ranged from 32.91 to 40.54. According to the industry distribution chart, PT Kalbe Farma Tbk ranks #779 out of 920 companies in the Drug Manufacturers industry, placing it in the top 84.7%.
Is PT Kalbe Farma Tbk's Days Payable too high?
PT Kalbe Farma Tbk's current Days Payable of 39.00 is near median its 10-year median of 36.45. Over the past 10 years, this metric has ranged from a low of 32.91 to a high of 40.54. The Drug Manufacturers industry median Days Payable is 90.84. PT Kalbe Farma Tbk's value of 39.00 is 57.1% below this industry median. Based on the distribution chart, PT Kalbe Farma Tbk ranks #779 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PT Kalbe Farma Tbk has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kalbe Farma Tbk's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, PT Kalbe Farma Tbk ranks #779 out of 920 companies for Days Payable. This places PT Kalbe Farma Tbk in the lower half of its industry. The industry median Days Payable is 90.84. PT Kalbe Farma Tbk's value of 39.00 is 57.1% below this benchmark. Historically, PT Kalbe Farma Tbk's own Days Payable has ranged from 32.91 to 40.54 over the past decade. While the company's 10-year median is 36.45 vs. the industry median of 90.84, PT Kalbe Farma Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kalbe Farma Tbk's current Days Payable of 39.00 is 57.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on PT Kalbe Farma Tbk and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kalbe Farma Tbk's current Days Payable is 39.00, which is near median its own 10-year median of 36.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kalbe Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk (FRA:LCLA) is currently considered Significantly Undervalued. The stock's GF Value™ is €0.07, compared to a current price of €0.05 — trading 32.9% below its estimated fair value. The current Days Payable is 39.00, which is near median its 10-year median of 36.45 and 57.1% below the Drug Manufacturers industry median of 90.84. PT Kalbe Farma Tbk's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For PT Kalbe Farma Tbk (FRA:LCLA), the current Days Payable is 39.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kalbe Farma Tbk (FRA:LCLA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kalbe Farma Tbk stock appears to be undervalued.
The current stock price of €0.05 is trading 32.9% below its estimated GF Value™ of €0.07.
GuruFocus considers PT Kalbe Farma Tbk to be Significantly Undervalued.
Key valuation signals for FRA:LCLA:
Days Payable: 39.00 (near median its 10-year median of 36.45)
GF Value™: €0.07 vs. price of €0.05 (32.9% below fair value)
Industry Position: 57.1% below the Drug Manufacturers median (#779 of 920)
No single metric tells the full story. See the FRA:LCLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
77GF Score
Get the complete analysis for FRA:LCLA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LCLA has been successfully added to your 
